In a mouse model, a new approach has led to the formation of new neural connections in the injured spinal cord, partially restoring lost function. However, further steps and studies are needed before potential treatments can be developed for humans
Get the latest international news and world events from around the world.
Humanity’s Endgame? We Built an AI That Will Command Us — MO Gawdat
🏦 Invest In Luxury Dubai Property https://londonreal.tv/dubai-ytd
🍿 Watch the full interview for free at https://londonreal.tv/gawdat.
In this powerful episode, Brian Rose sits down with former Google X exec and bestselling author Mo Gawdat 🧠 to explore the mind-blowing future of Artificial Intelligence 🤯. From the rise of machine learning to the ethical dangers of unchecked AI evolution ⚠️, this conversation uncovers why AI is the infant that could soon become our master.
🔥 Discover the truth about what’s coming
⚙️ Why we must act now to guide its growth
🧘♂️ And how mindfulness may be our only defense.
This one will change how you see the future 🌍💡
👉 Don’t miss it — hit play now and prepare your mind.
🚨 Learn To Make Money In Crypto:
💰The Investment club: https://londonreal.tv/club
💰Crypto & DeFi Academy: https://londonreal.tv/defi-ytd.
🔔 SUBSCRIBE ON YOUTUBE: http://bit.ly/SubscribeToLondonReal
Parkinson’s Patient Moves Freely Again After World-First Imp
Parkinson’s patient Thomas Matsson was the first in the world to receive 7 million lab-grown brain cells in 2023. Today, he can smell and play sports.
Researchers at Lund University in Sweden have successfully implanted 7 million lab-grown brain cells into a patient to treat Parkinson’s disease.
Swedish resident Thomas Matsson was the first in the world to test the method about a year ago.
Godfather of AI: How To Make Safe Superintelligent AI
The co-inventor of modern AI and the most cited living scientist believes he’s figured out how to ensure AI is honest, incapable of deception, and never goes rogue. Yoshua Bengio – Turing Award Winner and founder of LawZero – is disturbed by the many unintended drives and goals present in today’s AIs, their ability to tell when they’re being tested, and demonstrated willingness to lie. AI companies are trying to stamp these out in a ‘cat-and-mouse game’ that Yoshua fears they’re losing.
But Yoshua is optimistic: he believes the companies can win this battle decisively with a single rearrangement to how AI models are trained, and has been developing mathematical proofs to back up the claim. The core idea is that instead of training AI to predict what a human would say, or to produce responses we’d rate highly, we should train it to model what’s actually true.
Learn more & full transcript: https://80k.info/bengio.
Yoshua argues this new architecture, which he calls “Scientist AI,” is a small enough change that we could keep almost all the techniques and data we use to train frontier AIs like Claude and ChatGPT. And that the new architecture need not cost more, could be built iteratively, and might be more capable as well as more honest.
Until recently, the biggest practical objection to Scientist AI was simple: the world wants agents, and Scientist AI isn’t one. But in new research, Yoshua has extended the design and believes the same honest predictor can be turned into a capable agent without losing its \.
Wealthy Individuals Funding Science is Good for Everyone
Excellent article on the importance of private funding for cutting-edge science.
“The skepticism toward private science funding is part of a broader anti-capitalist sentiment, likely fueled by real affordability problems in housing, healthcare, and education. These concerns are understandable. But directing private capital toward fundamental science benefits everyone, and treating this the same as other uses of wealth only ensures that money flows into megayachts rather than research.”
Private wealth funded most of history’s scientific breakthroughs. Stigmatizing it now is holding us all back.
Kanvas makes the microbiome druggable—and the implications are massive
Kanvas looks amazing! They’re systematically deciphering microbiomes and developing clinical-stage interventions to improve patient outcomes in oncology and beyond. Very impressive! I’m also especially interested in their approach to maternal environmental enteric dysfunction (EED), which apparently affects 150M people!
Ever since the genomics revolution revealed how reliant the human organism is on its microscopic microbial cohabitants, the microbiome has been medicine’s most elusive frontier, promising better health if only we could untangle the trillions of interactions that influence nearly every facet of our physiology. But until now, effective medicines that harness the microbiome have been rare. Because of the diversity of microbial species and the complexity of host-to-microbe interactions, as well as the lack of a reliable, easily manufactured drug modality (the package that delivers a medicine’s therapeutic effect), the microbiome has been hard to treat, despite its importance to functions like immune response. Microbiome science has disappointed patients, doctors, founders, and investors.
That’s why DCVC is so excited about the cascade of recent developments at Kanvas Biosciences, which is moving the field beyond descriptive profiling of the microbiome to translating comprehensive biochemical insights into clinically useful products. In the past few weeks, the Princeton-based spatial biology company has kicked off a Phase 1 clinical trial for its first drug candidate, secured significant new backing from the Gates Foundation (closing a $48 million Series A financing, bringing Kanvas’s total funding to $78 million), and bolstered its scientific leadership by adding one of the most respected names in bioengineering to its board.
Clinical milestone
The most significant milestone in Kanvas’s evolution is the dosing of the first patients in a Phase I clinical trial for KAN-4. This live biotherapeutic product (LBP), resembling an ordinary pill, treats the colitis that many cancer patients develop after receiving immune checkpoint inhibitors (ICIs), allowing them to remain on the life-saving therapy longer.
One Type of Fat May Accelerate Brain Aging, But Scientists Say There’s a Fix
A higher level of the fat that gathers around organs has been linked to faster brain aging in a new study, with glucose and insulin the likely mediators.
The study, led by a team from Ben-Gurion University of the Negev (BGU) in Israel, suggests that reducing visceral fat can protect against brain atrophy.
Like other parts of the body, the brain doesn’t necessarily age at a consistent rate: wear and tear can increase or decrease, depending on numerous factors. Faster brain aging typically means a faster decline in mental performance, and a higher risk of brain diseases.
Specialized RNA molecules could counter ALS neurodegeneration
Misshapen proteins cause a mess of trouble—particularly in neurodegenerative diseases. But a new study suggests it’s possible that giving them a little bit of extra support could keep them working correctly, and even reverse the damage they have caused.
The new research focuses on one such aberrant protein, TDP-43, which binds to RNA in the cell’s nucleus and is responsible for regulating thousands of human genes. If TDP-43 turns from a healthy, liquid-like phase into diseased, fibrous solid-like aggregates, its presence can be fatal.
This protein is one of the key drivers of the diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)—a discovery first made by pioneering Penn Medicine scientists Virginia M.-Y. Lee, Ph.D., MBA, and the late John Trojanowski, MD, Ph.D.
Dynamically Tunable Singular States Through Air-Slit Control in Asymmetric Resonant Metamaterials
This study presents a novel method for dynamically tuning singular states in one-dimensional (1D) photonic lattices (PLs) using air-slit-based structural modifications. Singular states, arising from symmetry-breaking-induced resonance radiation, generate diverse spectral features through interactions between resonance modes and background radiation. By strategically incorporating air slits to break symmetry in 1D PLs, we demonstrated effective control of resonance positions, enabling dual functionalities including narrowband band pass and notch filtering. These singular states originate from asymmetric guided-mode resonances (aGMRs), which can be interpreted by analytical modeling of the equivalent slab waveguide. Moreover, the introduction of multiple air slits significantly enhances spectral tunability by inducing multiple folding behaviors in the resonance bands.